SMT112-3005 A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer by Mary Beth Wilwerding | Sep 3, 2026
BGB-A317-316 A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma by Mary Beth Wilwerding | Sep 3, 2026
RMC-6236-401 Expanded access program to treat patients with previously treated metastatic Pancreatic adenocarcinoma with Daraxonrasib by Mary Beth Wilwerding | Sep 2, 2026
C6461003 AN, INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER by Mary Beth Wilwerding | Sep 2, 2026
GI008 Colon adjuvant chemotherapy based on evaluation of residual disease by Mary Beth Wilwerding | Sep 2, 2026
